The Alpha-1 Foundation announced it will receive up to $1 million in grant matching funds from Talecris Biotherapeutics, Inc. to support research into alpha1-antitrypsin deficiency, a genetic condition in which low levels of the essential blood protein alpha1-proteinase inhibitor, can cause emphysema. Related posts Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize [...]
Alpha's tag archives
Alpha-1 Foundation Announces the Million Dollar Match Program Made Possible by a Talecris Biotherapeutics Grant
Posted by Dana in June 6th 2009
Recent Articles
-
- Vertex Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress
- AMAG Pharmaceuticals Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2010
- CardioNet, Inc. Reports Second Quarter 2010 Financial Results
- NPS Pharmaceuticals to Report Second Quarter 2010 Financial Results
- BioAlliance Pharma SA: A Record Turnover for Q2 2010 Reflecting the Successful US FDA Approval
- HealthStream Announces Second Quarter 2010 Results
- Simulations Plus Reports Third Quarter FY2010 Financial Results
- ZOLL Medical Corporation to Announce Third Quarter Results
- AngioDynamics Reports Strong Finish to Fiscal 2010
- Cubist Pharmaceuticals 2Q10 Total Net Revenues Up 29% to $168.5 Million
- Furiex Pharmaceuticals Announces Second Quarter 2010 Earnings Release and Conference Call
- Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the Second Quarter Ended June 30, 2010
- Biomet Announces Fourth Quarter and Fiscal Year 2010 Financial Results
- Allergan Announces Quarterly Conference Call
- Simulations Plus Reports Preliminary Revenues for Third Fiscal Quarter of FY2010
